The University of Chicago Header Logo


Mark J. Ratain to Diphtheria Toxin

This is a "connection" page, showing publications Mark J. Ratain has written about Diphtheria Toxin.
Connection Strength

  1. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73.
    View in: PubMed
    Score: 0.041
  2. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405.
    View in: PubMed
    Score: 0.040
  3. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997 Jan; 33 Suppl 1:S34-6.
    View in: PubMed
    Score: 0.037
  4. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.